INT-2104

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameINT-2104
Drug Alias NameINT-2104
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionT lymphocytes modulatorsNatural killer cells modulatorsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInterius BioTherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInterius BioTherapeutics IncKite PharmaWuXi ATU (Hong Kong) Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A